Letters to the editor: Renal cancer after busulphan treatment for chronic myeloid leukemia: Therapeutic implications

Foa, P.; Iurlo, A.; Maiolo, Anna Teresa

doi:10.1093/oxfordjournals.annonc.a058569

Cited by 5 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy with Busulphan or Hydroxyurea (HU) has been used to reduce huge splenomegaly and/or severe leuco-thrombocytosis (Manoharan & Pitney, 1984;Lofvenberg et al, 1990). However, the prolonged administration of Busulphan has been associated with an increased risk of leukaemic evolution (Stott et al, 1977;Brandt & Anderson, 1995) as well as with other secondary tumours (Foa et al, 1993), while HU is often unable to reduce splenic enlargement and, most recently, a certain leukaemogenic potential has been suggested (Sterkers et al, 1998). In addition, until now, no improvement in survival duration has been statistically evidenced with these drugs (Hasselbach & Jensen, 1990;Rupoli et al, 1994).…”

mentioning

confidence: 99%

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia

et al. 2002

View full text Add to dashboard Cite

/l] received low-dose Melphalan (2AE5 mg/3 times/week) to evaluate the efficacy and toxicity of this approach. Among 99 evaluable patients, 66 (66AE7%) achieved a response after a median time of 6AE7 months: 26 (26AE3%) had a normalization of all clinical and haematological parameters (complete response, CR) and 40 (40AE4%) showed an improvement > 50% (partial response, PR). Thirty-three patients (33AE3%) were resistant. Reversible haematological toxicity was the most common complication. Median durations of CR and PR were 28AE4 and 26 months respectively: median survival of CR + PR patients was 71AE2 months (95%CI: 33AE8-108AE7) versus 36AE5 months (95%CI: 24AE5-48AE5) for the non-responders (log-rank test, P ¼ 0AE002). In the multivariate analysis, the following variables were significantly associated with a shorter survival: anaemia [hazard risk (HR) ¼ 2AE7], WBC count > 20 · 10 9

show abstract

mentioning

confidence: 99%

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia

et al. 2002

View full text Add to dashboard Cite

show abstract

“…However, the prolonged administration of busulfan [26] or sequential use of busulfan and hydroxyurea [27] has been associated with an increased incidence of leukemic evolution as well as with other secondary tumors, such as renal cell carcinoma [28]. …”

Section: Current Therapiesmentioning

confidence: 99%

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

et al. 2012

View full text Add to dashboard Cite

Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms, which have a significant negative impact on patients’ quality of life. It may also be present in patients with advanced polycythemia vera (PV) or essential thrombocythemia (ET). Until recently, none of the therapies used to treat MF were particularly effective in reducing splenomegaly. The discovery of an activating Janus kinase 2 (JAK2) activating mutation (JAK2V617F) that is present in almost all patients with PV and in about 50-60 % of patients with ET and PMF led to the initiation of several trials investigating the clinical effectiveness of various JAK2 (or JAK1/JAK2) inhibitors for the treatment of patients with ET, PV, and MF. Some of these trials have documented significant clinical benefit of JAK inhibitors, particularly in terms of regression of splenomegaly. In November 2011, the US Food and Drug Administration approved the use of the JAK1- and JAK2-selective inhibitor ruxolitinib for the treatment of patients with intermediate or high-risk myelofibrosis, including PMF, post-PV MF, and post-ET MF. This review discusses current therapeutic options for splenomegaly associated with primary or secondary MF and the treatment potential of the JAK inhibitors in this setting.

show abstract

“…[ 6 ] In addition, treatment associated second malignancies (usually leukemias and lymphomas but also solid tumors) have been described in long term survivors of Hodgkin's lymphoma (HL) [ 7 , 8 ], Non Hodgkin's lymphoma (NHL) [ 9 - 11 ] and in various pediatric tumors. [ 12 , 13 ] There have been sporadic case reports of hairy cell leukemia [ 14 ], chronic myeloid leukemia [ 15 ], multiple myeloma [ 16 , 17 ], NHL [ 18 ], HL [ 19 ] and testicular carcinoma. [ 20 ] Nishikubo et al, described a serie of eight patients with renal cell cancer and lymphoid malignancies.…”

Section: Introductionmentioning

confidence: 99%

Coexistence between renal cell cancer and Hodgkin's lymphoma: A rare coincidence

Jimenez

2006

BMC Urol

View full text Add to dashboard Cite

Background: Renal cell carcinoma is the most common kidney tumor in adults and accounts for approximately 3% of adult malignancies. An increased incidence of second malignancies has been well documented in a number of different disorders, such as head and neck tumors, and hairy cell leukemia. In addition, treatment associated second malignancies (usually leukemias and lymphomas but also solid tumors) have been described in long term survivors of Hodgkin's lymphoma (HL), Non Hodgkin's lymphoma and in various pediatric tumors.

show abstract

Letters to the editor: Renal cancer after busulphan treatment for chronic myeloid leukemia: Therapeutic implications

Cited by 5 publications

References 1 publication

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Coexistence between renal cell cancer and Hodgkin's lymphoma: A rare coincidence

Contact Info

Product

Resources

About